These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21559023)

  • 21. Field assays with anti-malarial vaccines: phase III protocols.
    Sanchez T
    Rev Inst Med Trop Sao Paulo; 1992 Apr; 34 Suppl 9():S24-7. PubMed ID: 1340629
    [No Abstract]   [Full Text] [Related]  

  • 22. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

  • 23. Summary of International Trials Working Group.
    Nzila N
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1423-5. PubMed ID: 1466972
    [No Abstract]   [Full Text] [Related]  

  • 24. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.
    Chesney MA; Lurie P; Coates TJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 May; 9(1):30-5. PubMed ID: 7712232
    [No Abstract]   [Full Text] [Related]  

  • 25. On the efficiency of targeted clinical trials.
    Maitournam A; Simon R
    Stat Med; 2005 Feb; 24(3):329-39. PubMed ID: 15551403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can non-randomized trials be considered to be equivalent to randomized trials in forensic mental health?
    Leese M
    Crim Behav Ment Health; 2005; 15(2):121-2. PubMed ID: 16470506
    [No Abstract]   [Full Text] [Related]  

  • 27. Reporting and exclusion of sexual and gender minorities in cancer clinical trials.
    Ludmir EB; Espinoza AF; Jethanandani A; Lin TA; Mainwaring W; Miller AB; Das P
    Int J Cancer; 2020 Apr; 146(8):2360-2361. PubMed ID: 31584188
    [No Abstract]   [Full Text] [Related]  

  • 28. The gold standard's flexible alloy: adaptive designs on the advance.
    Millard WB
    Ann Emerg Med; 2012 Aug; 60(2):22A-27A. PubMed ID: 22993830
    [No Abstract]   [Full Text] [Related]  

  • 29. CONSORT 2010.
    Chen YL; Yang KH
    Lancet; 2010 Jul; 376(9737):230. PubMed ID: 20656116
    [No Abstract]   [Full Text] [Related]  

  • 30. The quality of randomised controlled trials may be better than assumed.
    del Giglio A; Costa LJ
    BMJ; 2004 Jan; 328(7430):24-5. PubMed ID: 14703541
    [No Abstract]   [Full Text] [Related]  

  • 31. Q&A: Rajeshwari Sridhara, Robert Temple on trial design. Interviewed by Suzanne Rose.
    Sridhara R; Temple R
    Cancer Discov; 2013 Mar; 3(3):245. PubMed ID: 23475863
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical trials: the gold standard for evaluation of therapy.
    Meinert CL
    Ophthalmology; 1996 Jun; 103(6):869-70. PubMed ID: 8643240
    [No Abstract]   [Full Text] [Related]  

  • 33. Bias control in clinical trials: masking or blinding.
    Galvez-Olortegui JK; Gonzales-Saldaña J; Garcia-Gomez I; Silva-Ocas I; Gutierrez-Arana J; Galvez-Olortegui T; Condor-Rojas YC
    Medwave; 2015 Dec; 15(11):e6349. PubMed ID: 26731671
    [No Abstract]   [Full Text] [Related]  

  • 34. General keynote: clinical trial design.
    Berry DA
    Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S114-6; S122-3. PubMed ID: 12586099
    [No Abstract]   [Full Text] [Related]  

  • 35. The necessity of placebo application in psychotropic drug trials.
    Benkert O; Maier W
    Pharmacopsychiatry; 1990 Sep; 23(5):203-5. PubMed ID: 2251299
    [No Abstract]   [Full Text] [Related]  

  • 36. Assessment of quality of life in clinical trials of the British Medical Research Council.
    Machin D
    J Natl Cancer Inst Monogr; 1996; (20):97-102. PubMed ID: 8750478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of therapeutic research on informed consent and the ethics of clinical trials: a medical oncology perspective.
    Daugherty CK
    J Clin Oncol; 1999 May; 17(5):1601-17. PubMed ID: 10334550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
    Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
    Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inclusion and exclusion criteria and the problem of describing homogeneity of study populations in clinical trials.
    Porzsolt F; Wiedemann F; Becker SI; Rhoads CJ
    BMJ Evid Based Med; 2019 Jun; 24(3):92-94. PubMed ID: 30567938
    [No Abstract]   [Full Text] [Related]  

  • 40. Bias, Operational Bias, and Generalizability in Phase II/III Trials.
    Freidlin B; Korn EL; Abrams JS
    J Clin Oncol; 2018 Jul; 36(19):1902-1904. PubMed ID: 29698104
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.